Untitled Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
First Amendment
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of
report (Date of earliest event
reported)
|
October 30,
2018
|
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
10524 Moss Park Rd. Ste-204-357
|
|
|
Orlando, FL
|
32832
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407) 996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
EXPLANATORY NOTE
This First Amendment to Form 8K is being filed for the purpose of
correcting minor typographical errors and clarifying Mr.
Dave’s educational background information.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On October 31, 2018, the
Board of Directors (the “Board”) of MEDITE Cancer
Diagnostics, Inc. (the “Company”) held a meeting
whereby it accepted the resignation of Stephen Von Rump as Chief
Executive Officer and Director of the Company, effective
immediately. Mr. Von Rump was thereafter appointed by the Board as
Chief Strategy Officer of the Company to serve until his
resignation or termination.
On
October 31, 2018, the Board thereafter, by unanimous consent,
appointed Elmar A. Dave to the position of Chief Executive Officer
of the Company to serve until such time as his removal or
resignation. Mr. Dave has been engaged by the Company as a
Consultant, and shall continue under the terms of his existing
Consulting Agreement until its expiration, whereby the Company
shall negotiate an Executive Employment Agreement with Mr. Dave
upon terms mutually acceptable to the parties.
Elmar A. Dave, Age 41, Chief Executive Officer
Elmar A. Dave is the Chief Executive Officer of MEDITE Cancer
Diagnostics, Inc. and brings over 19 years of experience in senior
operations management specializing in international manufacturing,
product development, process management, and global
commercialization of medical technologies, operational
restructuring, and corporate strategy. From November, 2014 through
May, 2015, Mr. Dave served as Chief Executive Officer and Board
Member of Eyeformatics located in Norwich CT. From May 2015
through March 2016, Mr. Dave served as Chief Operating Officer and
Board Member of Bellebridge, located in Shelton, CT. From October,
2015 through January 2017, Mr. Dave served as Chief Executive
Officer and Board member of Sonocine located in Reno, NV. From
January, 2017 through the present, Mr. Dave served as Chief
Executive Officer of JMC North America located in Reno, NV. He
holds a Bachelor of Science Degree in Operations Management and
Industrial Manufacturing from Technische Akademie in Hamburg,
Germany, and a Master of Business Administration Degree in
Corporate Finance, Entrepreneurship and Innovation from New York
University. Except as otherwise set forth herein, Mr. Dave does not
presently, and has not in the past, served as a board member or
officer of any company required to file reports with the Securities
and Exchange Commission.
Item
9.01
Financial
Statements and Exhibits
(d) Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Resignation
Letter of Stephen Von Rump Dated October 30, 2018
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date:
November 7, 2018
|
By:
|
/s/ Elmar A. Dave
|
|
|
|
Elmar
A. Dave
|
|
|
|
Chief
Executive Officer
|